BIOMARKERcenter is First Comprehensive and Quality Assured Biomarker
Solution Available to the Pharmaceutical Industry
PHILADELPHIA and LONDON, June 17 /PRNewswire-FirstCall/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, announced today the launch of BIOMARKERcenter, a unique comprehensive resource for biomarker intelligence. This new solution will be the first to provide the pharmaceutical industry with a framework for assessing the potential of a biomarker and to be alerted of any changes in their status.
BIOMARKERcenter covers the biomarkers identified in literature, patents, conferences, clinical trial information, and other sources for all major therapeutic areas: oncology, cardiovascular diseases, diabetes, respiratory disorders, autoimmune diseases and neurological disorders. For each therapy area, it includes not only biomarkers with established clinical usage, but also emerging uses for the biomarker. Each record has been manually created by a team of Thomson Reuters experts and provides a unique report on the biomarker using a novel lifecycle model. Other data provided will include the name, classification, biological entities/processes involved, associated drugs, role or utilities, measurement techniques, regulatory status and related diagnostic kits.
Biomarkers are measurable indicators which can be used to define a biological state. Using Biomarkers as part of a pharmaceutical R&D program can increase the success of the project by encouraging innovation, improving efficiency, saving costs and delivering a valuable advantage over competitors.
"BIOMARKERcenter is the first reliable and comprehensive database of
biomarkers available to the pharmaceutical and diagnostic industries. It
sets a new standard for the presentation and analysis of Biomarker
information," said Jon Brett-Harris, EVP Pharmaceutical and Chemicals
Markets, Thomson Reuters. "B
|SOURCE Thomson Reuters|
Copyright©2008 PR Newswire.
All rights reserved